stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) Total debt
RadNet, Inc.'s total debt at the end of fiscal 2025 was $1.1B, up 7.25% from $1.0B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.3B. Over the past ten years it has ranged from $606.3M (fiscal 2015) to $1.1B (fiscal 2025) — the current reading is the highest in ten years. RadNet, Inc. ranks 16th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.1B | 7.25% |
| FY2024 | $1.0B | 25.15% |
| FY2023 | $812.1M | (10.70%) |
| FY2022 | $909.3M | 10.83% |
| FY2021 | $820.5M | 13.70% |
| FY2020 | $721.7M | (5.04%) |
| FY2019 | $760.0M | 13.09% |
| FY2018 | $672.0M | 10.34% |
| FY2017 | $609.0M | (4.72%) |
| FY2016 | $639.2M | 5.42% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $1.3B | 22.76% |
| Mar 2026 | $1.1B | (2.38%) |
| Dec 2025 | $1.1B | 1.78% |
| Sep 2025 | $1.1B | (0.59%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ICLR ICON PLC compare | $3.4B |
| SHC Sotera Health Company compare | $2.2B |
| QGEN QIAGEN N.V. compare | $1.6B |
| RDNT RadNet, Inc. | $1.3B |
| ADPT Adaptive Biotechnologies Corporation compare | $334.9M |
| BLLN BillionToOne, Inc. compare | $89.1M |
| CDNA CareDx, Inc. compare | $35.2M |
| VCYT Veracyte, Inc. compare | $14.0M |
| GRAL GRAIL, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement